Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
odronextamab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Odronextamab + chemotherapy is an investigational combination therapy being studied primarily for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Odronextamab is a fully human, IgG4-based bispecific monoclonal antibody that binds CD20 on malignant B cells and CD3 on cytotoxic T cells, physically bridging these cell types to enable direct T cell–mediated cytotoxicity against CD20+ B cells. This mechanism is distinct from classic monoclonal antibodies, providing a targeted immunotherapy approach by activating T cells independently of their conventional antigen recognition pathways. The chemotherapy component varies but typically refers to conventional cytotoxic agents used in standard lymphoma regimens. Clinical trials are investigating the efficacy and safety of odronextamab in combination with chemotherapy, compared to the established regimen of rituximab plus chemotherapy, especially in patient populations with relapsed or refractory disease[1][3][7][8].
- Brand names
- None known
- Other names
- odronextamab + chemotherapy
02
Targets
CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on odronextamab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on odronextamab + chemotherapy.